ACTRN12607000275460招募中1 期
A Phase I, Single Ascending Dose, Safety and Pharmacokinetic Study of PN0621 in Healthy Volunteers
Peptech Limited0 个研究点目标入组 30 人开始时间: 2007年5月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- All
入选标准
- •BMI - Body mass Index' 19 to 29, nromal or clinically acceptable 'ECG - Electrocardiogram'
排除标准
- •Donation or loss of more than 400ml blood within 3 months of study, history of infection, screen positive to Tuberculosis, Hepatitis C, Hepatisis B or Human immunodeficiency virus (HIV)
研究者
相似试验
已完成
1 期
Healthy Volunteer, Single Ascending Dose Study of TP-317Inflammatory bowel diseaseOral and Gastrointestinal - Inflammatory bowel diseaseACTRN12624000239561Thetis Pharmaceuticals LLC24
进行中（未招募）
1 期
A clinical study performed with increasing doses (single dose per patient) to evaluate safety, tolerability and pharmacokinetic of NicaPlant® in aneurysmal subarachnoid haemorrhage patients needing to undergo an aneurysm clipping operatioAneurysmal subarachnoid haemorrhageMedDRA version: 20.1 Level: PT Classification code 10008111 Term: Cerebral haemorrhage System Organ Class: 10029205 - Nervous system disordersEUCTR2016-004521-17-ATBIT Pharma GmbH14
已完成
1 期
A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of EARLI-001 in subjects with lung cancerLung cancerACTRN12620001178932Earli, Pty Ltd10
已完成
不适用
Ascending single dose study of the safety, tolerability, and pharmacokinetics of PRM-151 administered to healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF)NL-OMON33156Centre for Human Drug Research32
已完成
1 期
PAT-SM6 in Patients with Recurrent In-Transit Cutaneous MelanomaRecurrent in-transit cutaneous melanomaCancer - Malignant melanomaSkin - Other skin conditionsACTRN12610000733077Patrys Limited9